Document is current
Any future updates will be listed below
-
Authors
Castagnaviz, Vanessa
Fenzl, Anna
Gnant, Michael
Bartsch, Rupert
-
Funding
Funding for this research was provided by:
Paracelsus Medical University
- License Information
-
More Information
Article History
Accepted: 9 July 2025
First Online: 31 July 2025
Interessenkonflikt
: V. Castagnaviz: Speaking Honoraria: Daiichi Sankyo, Astra Zeneca, Novartis, Roche. Adivisory board/Consulting Honoraria: Novartis, Roche, Pfizer. Travel and conference attendance: Daiichi Sankyo, Astra Zeneca, Gilead, Pierre-Fabre, Eli-Lilly, Menarini-Stemline, Roche, Novartis, Pfizer. M. Gnant: Personal fees/travel support from Amgen, AstraZeneca, Bayer, DaiichiSankyo, EliLilly, EPG Health (IQVIA), Menarini-Stemline, MSD, Novartis, PierreFabre, Veracyte. R. Bartsch: Advisory Role: Astra-Zeneca, Daiichi, Eisai, Eli-Lilly, Gilead, Gruenenthal, MSD, Novartis, Pfizer, Pierre-Fabre, Roche, Seagen, Stemline. Lecture Honoraria: Astra-Zeneca, BMS, Daichi, Eisai, Eli-Lilly, Gilead, Gruenenthal, MSD, Novartis, Pfizer, Pierre-Fabre, Roche, Seagen, Stemline. Research Support: Daiichi, MSD, Novartis, Roche. A. Fenzl gibt an, dass kein Interessenkonflikt besteht.
